about
Breast radiotherapy (RT) using tangential fields (TgF): a prospective evaluation of the dose distribution in the sentinel lymph node (SLN) area as determined intraoperatively by clip placement.Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography.PET-imaging as a useful tool for early detection of the relapse site in the management of primary myeloid sarcoma.Neuropsychological Correlates of Brain Perfusion SPECT in Patients with Macrophagic Myofasciitis.Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation.Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.Positron Emission Tomography With 18F-Fluorodeoxyglucose in Patients With Sickle Cell Acute Chest SyndromeLymph node imaging: basic principles.Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma.FDG-PET/CT Brain Findings in a Patient With Macrophagic Myofasciitis.Whole body MRI and PET/CT in haematological malignancies.Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience.Whole-body diffusion-weighted imaging in lymphoma.FDG PET/CT imaging as a biomarker in lymphoma.Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.Usefulness of T2 ratio in the diagnosis and prognosis of cardiac amyloidosis using cardiac MR imaging.Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria).Cerebral 18F-FDG PET in macrophagic myofasciitis: An individual SVM-based approach.Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body DiseasePredictive value of brain 18F-FDG PET/CT in macrophagic myofasciitis?: A case report.Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer.Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma.Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background.Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.[18F]fluorodeoxyglucose triple-head coincidence imaging as an adjunct to 131I scanning for follow-up of papillary thyroid carcinoma.[123I-Ioflupane brain scintigraphy (DaTScan) to demonstrate loss of nigrostratal dopaminergic neurons: principles and applications].Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma.Quantitative lung perfusion scan as a predictor of aerosol distribution heterogeneity and disease severity in children with cystic fibrosis.Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.Brain 18F-FDG PET Metabolic Abnormalities in Macrophagic Myofasciitis: Are They Stable?High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.Clinical routine use of dopamine transporter imaging in 516 consecutive patients.Subacute dopa-responsive Parkinsonism after successful surgical treatment of aqueductal stenosis.Brain 18F-FDG PET Metabolic Abnormalities in Patients with Long-Lasting Macrophagic Myofascitis.
P50
Q34303444-3F3A78B4-D655-4C1B-9C41-A00C66FDCC54Q34307104-CFF4426B-1FA2-4E72-9061-350773D0DEE1Q34595796-BE8857B6-C868-47A1-B0CA-CCA5C4CD1CCAQ35648203-FF03C91B-C728-4B59-8710-B5A0B9A8ECB0Q35925442-C7520BB7-DEB3-401E-B79A-22AFEAB3E6DBQ35961361-23605C79-2D00-4F9E-ABFF-2CF61BDAB5E2Q36151335-B0C45617-15AA-4FEA-8685-27742EDC7035Q36394517-B4D2606D-334C-4B84-84DA-C67EB91E8C37Q36409184-8812DACE-C01A-4E81-BA64-CCBF2063D427Q36605022-EB6381B5-4898-4A60-8BD8-305A4ADCC61BQ36963742-AB749C44-9460-4D58-9E1A-83EAA07B7FDBQ37401565-49D61842-2C3B-4894-BD2B-236AF34E7381Q37794481-253E4313-0DFA-4F15-A908-3DF726E0CF13Q38312367-37AC7C0A-6A9E-4936-8C23-4E228258CD52Q38393419-1EB5E7E6-64E9-4C3A-8F84-11436322F088Q38969595-FCE92F0B-C026-4157-8AC3-73F71C7C0A96Q38984069-6099A1D4-121C-41F1-BA90-65C543652C9EQ39976687-48F84647-11EB-4879-8956-3D3F6A54F704Q41007460-F3E5C043-F85C-4D53-B72D-34DA9CDEC4FBQ41959686-DEE3C2BB-E109-4623-AB02-44E025F030A9Q42005099-52632BE5-08DB-46CD-8F85-338BB76B4A53Q42178065-EAA0314F-F7AE-4C58-9D1B-5EADDC516FB6Q42562978-3063B692-170B-4A98-A40D-66F97C1D1068Q42603371-16D512CB-2C12-43E0-AB38-D7BCB773E11EQ42813030-DABC0419-E79A-4F90-B9CA-D979B3C4523CQ42928472-565EE023-0D4E-4BB4-B876-6859F3FC3517Q43253516-E7A266F0-448A-4EA3-A7C7-F02960EF8793Q44021769-EEF324D8-D8E3-47FA-B13A-04D973D607C9Q44619237-9BBF7B61-6BBA-4672-B1A1-19D68B5DE5FCQ44654475-1981EFBA-F9E4-419F-87F1-314B0489E2BBQ46086916-7BE129BA-9B06-480E-8CFB-0E02E0A445B2Q46463095-ABFCE62A-0746-4962-AB13-5FB53D8BF66CQ47687260-B95BB62B-CE04-4D83-8D06-C8B37CFF22D9Q47976229-281B3136-AC61-4EB6-8A50-D895ADAA788DQ48177831-D61E61FE-FD08-4C95-BE5E-81938E770944Q48259777-74C85B57-B886-4EF9-9A8D-0A1E16D668DAQ48271027-7E7A5A85-6DD2-47D5-B255-72FE8A888151Q48345075-51BAC186-E4FB-42B0-97C2-4439B3D5ABD6Q48409986-9B77BA00-844E-49A5-A014-0E34DF610005Q48468233-57A84A10-F52A-4CB6-8A05-B4E372675A5A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emmanuel Itti
@ast
Emmanuel Itti
@en
Emmanuel Itti
@es
Emmanuel Itti
@nl
Emmanuel Itti
@sl
type
label
Emmanuel Itti
@ast
Emmanuel Itti
@en
Emmanuel Itti
@es
Emmanuel Itti
@nl
Emmanuel Itti
@sl
prefLabel
Emmanuel Itti
@ast
Emmanuel Itti
@en
Emmanuel Itti
@es
Emmanuel Itti
@nl
Emmanuel Itti
@sl
P106
P31
P496
0000-0003-1578-4058